Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

This study is testing a personalized mRNA vaccine (ABO2102) that targets a specific mutation in the KRAS gene — a mutation found in many types of cancer — to see if it can help the immune system fight advanced solid tumors. **You may be eligible if...** - You are 18 years or older - You have an advanced or metastatic solid tumor (such as pancreatic cancer or lung cancer) with a KRAS mutation, confirmed by testing - Your cancer has progressed or you could not tolerate at least one prior line of treatment **You may NOT be eligible if...** - You do not have a KRAS mutation in your tumor - You have active autoimmune disease requiring systemic treatment - You have active brain metastases - You have serious heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.